<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Caprylidene: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Caprylidene: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Caprylidene: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="95498" href="/d/html/95498.html" rel="external">see "Caprylidene: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F24652170"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Axona</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F24657374"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Medical Food</li></ul></div>
<div class="block doa drugH1Div" id="F24652180"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a3041b3d-3f11-47c1-815e-01b475c1f691">Alzheimer disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Alzheimer disease (AD):</b> Oral: Initial: 10 g once daily for 2 days; increase dose in 10 g increments every 2 days until reaching 40 g once daily on day 7; titrate slower if the patient experiences adverse events; Maintenance: 40 g once daily</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> If adverse events occur, discontinue caprylidene until symptoms resolve (generally within 2 to 3 days). Over-the-counter medications such as simethicone, antacids, and antidiarrheals may be useful for treating mild to moderate GI side effects. Restart caprylidene with the initial dose.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990279"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50987525"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F24143202"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Diarrhea (10% to 24%), nausea (10% to 20%), abdominal distention (17%), flatulence (15% to 17%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (5%) </p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness (7%), headache (6%), fatigue (4%), pain (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (10%), dyspepsia (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (4%), rhinitis (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abdominal distress, GI inflammation (exacerbation), increased blood urea nitrogen, increased serum creatinine, increased serum triglycerides, increased uric acid, syncope</p></div>
<div class="block coi drugH1Div" id="F24652171"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Allergy to milk or soy</p></div>
<div class="block war drugH1Div" id="F24652172"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Ketoacidosis: Use with caution in patients at risk for ketoacidosis such as patients with a history of alcohol abuse and poorly controlled diabetes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with a history of bradycardia, hypotension, or among patients taking medications that may induce these effects (eg, antihypertensives and cholinesterase inhibitors); fainting and dizziness has been infrequently reported among these groups. Use a gradual dose titration in patients at risk and emphasize administration after meals.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal disease: Gastrointestinal (GI) adverse effects (eg, abdominal cramping, diarrhea, dyspepsia) may result due to the rapid hydrolysis of medium-chain triglycerides in the gut and the resultant accumulation of high concentration of medium-chain fatty acids in the small intestine. Severe episodic diarrhea may occur with overusage.  Use with caution in patients with a history of GI inflammatory conditions such as irritable bowel syndrome, diverticular disease, chronic gastritis, and severe gastroesophageal reflux disease. OTC medications such as simethicone, antacids, and antidiarrheals may be useful for treating mild to moderate GI effects; advise patients to see healthcare provider if symptoms persist.</p>
<p style="text-indent:-2em;margin-left:4em;">• Metabolic syndrome: Elevated triglyceride values have been observed in patients with probable metabolic syndrome.  Periodically monitor triglyceride levels in patients who meet at least 3 of the following 5 criteria indicative of metabolic syndrome: Elevated waist circumference (≥40 inches in men, ≥35 inches in women), blood pressure ≥130/85 mm Hg, triglyceride ≥150 mg/dL, reduced fasting HDL (&lt;40 mg/dL in men, &lt;50 mg/dL in women), and fasting glucose ≥100 mg/dL.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with a history of renal dysfunction; mild increases in blood urea nitrogen (BUN), creatinine, or uric acid were reported in clinical trials.  Routine renal function monitoring is recommended in patients with a history of renal dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Component ingredients: Product contains caseinate (milk-derived protein), whey (milk), and lecithin (soy). Do not use in patients allergic to these component ingredients or milk or soy.</p></div>
<div class="block foc drugH1Div" id="F56638752"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Powder for Reconstitution, Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Axona: Caprylic triglycerides (40g)</p></div>
<div class="block adm drugH1Div" id="F24652184"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: The contents of each packet of caprylidene should be added to 4 to 8 oz (118 to 236 mL) of water or other liquids, shaken or blended until fully mixed, and consumed 15 to 30 minutes after a full meal (preferably breakfast or lunch). Consumption following meals containing fats and proteins or adding ice to the drink may slow the digestion of MCTs and reduce the likelihood of developing GI symptoms; tolerability can also be improved if the drink is sipped over 30 minutes instead of consumed all at once.</p></div>
<div class="block use drugH1Div" id="F24034662"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Alzheimer disease:</b> For clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer disease (AD). Caprylidene is a medical food containing a proprietary formulation of medium-chain triglycerides (MCTs), specifically caprylic triglyceride.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> A medical food is formulated to be administered enterally under the supervision of a physician and is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements are established by medical evaluation. Medical foods are not drugs and, therefore, are not subject to any FDA regulatory requirements that specifically apply to drugs (eg, premarket review or approval or proof of safety and efficacy).</p></div>
<div class="block cyt drugH1Div" id="F24069987"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F24069984"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block mop drugH1Div" id="F24652186"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Periodic triglyceride levels in patients who meet criteria indicative of metabolic syndrome; routine renal function tests in patients with a history of renal dysfunction; periodic monitoring of hepatic function in patients with hepatic cirrhosis</p></div>
<div class="block pha drugH1Div" id="F24652175"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Induces hyperketonemia to provide an alternative energy substrate to glucose in the brain of patients with Alzheimer disease</p></div>
<div class="block phk drugH1Div" id="F24652177"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Metabolism: Processed by lipases in the gut to medium-chain fatty acids (MCFAs); MCFAs under obligate oxidation in the liver and beta-oxidation in the liver mitochondria to form acetyl-CoA and acetoacetyl-CoA.  Acetyl-CoA and acetoacetyl-CoA when in excess are combined to form 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) which forms acetoacetate and beta-hydroxybutyrate (ie, ketone bodies) by HMG-CoA lyase.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Axona (caprylidene) [prescribing information]. Broomfield, CO: Accera; November 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24413538">
<a name="24413538"></a>Sharma A, Bemis M, Desilets AR. Role of medium chain triglycerides (Axona) in the treatment of mild to moderate Alzheimer's disease. <i>Am J Alzheimers Dis Other Demen</i>. 2014;29(5):409-414.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caprylidene-drug-information/abstract-text/24413538/pubmed" id="24413538" target="_blank">24413538</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 95044 Version 29.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
